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Abstract: Polycystic ovary syndrome (POS) is one of the most common endocrine abnormalities affec-
ting women of reproductive age. It is a cause of significant social embarrassment and emotional distress.
The pathogenesis of the disease is not yet fully understood, but it is thought to be a complex multige-
nic disorder, including abnormalities in the hypothalamic-pituitary axis, steroidogenesis, and insulin
resistance. The main diagnostic findings of the syndrome are: hyperandrogenism, chronic anovulation
and polycystic ovarian morphology seen on ultrasound. Hyperandrogenism is generally manifested as
hirsutism, acne, seborrhea, androgenic alopecia and, in severe cases, signs of virilization. Treatment may
improve the clinical manifestations of excess androgen production, normalize menses and ameliorate
metabolic syndrome and cardiovascular complications. This article reviews the diagnosis, clinical mani-
festations, metabolic complications, and treatment of the syndrome. Early diagnosis and the consequent
early treatment may prevent metabolic complications and emotional distress that negatively impact the
patients' quality of life. 
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Resumo: A síndrome do ovário policístico (SOP) é uma das endocrinopatias mais freqüentes nas mulhe-
res em idade reprodutiva. Caracteriza-se por morbidade elevada devido aos aspectos estéticos e por
repercussões metabólicas importantes. Embora a sua patogênese permaneça incompletamente conhe-
cida, acredita-se numa desordem multigênica complexa, incluindo anormalidades no eixo hipotálamo-
hipofisário, esteroidogênese e resistência insulínica. Os achados principais para o diagnóstico são: hipe-
randrogenismo, anovulação crônica e ovários policísticos à ultrassonografia. As manifestações dermato-
lógicas do hiperandrogenismo incluem: hirsutismo, acne, seborréia, alopecia e, em casos mais graves,
sinais de virilização. Existe considerável heterogeneidade nos achados clínicos e também pode haver
variação na mesma paciente com o passar do tempo. O tratamento visa reduzir as manifestações do
hiperandrogenismo, restaurar os ciclos ovulatórios regulares e corrigir a síndrome metabólica. Este arti-
go apresenta revisão da fisiopatologia, diagnóstico e tratamento da síndrome do ovário policístico.
Enfatiza-se a importância do diagnóstico e tratamento precoces no intuito de prevenir as complicações
metabólicas e a repercussão emocional que afeta a qualidade de vida das pacientes. 
Palavras-chave:  Acantose nigricans; Acne vulgar; Alopecia; Hiperandrogenismo; Síndrome do ovário
policístico
Received on 03.12.2009.
Approved by the Advisory Board and accepted for publication on 02.06.2010. 
* Work conducted at the Dermatology Service, Clementino Fraga Filho University Hospital - Federal Universaity of Rio de Janeiro (UFRJ) - Rio de Janeiro (RJ), Brazil.
Conflict of interest: None / Conflito de interesse: Nenhum
Financial funding: None / Suporte financeiro: Nenhum
1 Specialist in Clinical Medicine and Dermatology – Post-graduate student, Dermatology Service, Federal University of Rio de Janeiro (UFRJ) - Rio de Janeiro 
(RJ), Brazil.
2 Specialist in Clinical Medicine with postgraduate training in dermatology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
3 PhD in Dermatology from the Federal University of Sao Paulo – Professor (PhD), Department of Dermatology, Federal University of Sao Paulo – Sao Paulo 
School of Medicine (Unifesp – EPM) – Sao Paulo, Brazil.
4 Specialist in Dermatology - Assistant Professor of Dermatology, Faculty of Medicine, Federal University of Rio de Janeiro (UFRJ); Assistant Professor of 
Dermatology, Santa Casa de Misericordia do Rio de Janeiro (SCMRJ); Assistant Professor of Dermatology, Souza Marques Technical-Educational Foundation - 
Rio de Janeiro (RJ), Brazil.
5 PhD in Dermatology, Federal University of Rio de Janeiro – Professor (PhD) of Dermatology, Faculty of Medicine, Federal University of Rio de Janeiro; Professor 
(PhD) of Dermatology, Souza Marques Technical-Educational Foundation - Rio de Janeiro (RJ), Brazil.
©2011 by Anais Brasileiros de Dermatologia
REVIEW
111
An Bras Dermatol. 2011;86(1):111-9.
INTRODUCTION
Polycystic ovary syndrome (PCOS), originally
described in the 1930s by Stein and Leventhal, is one
of the most common endocrinopathies in women of
reproductive age. 1 It is often characterized by
hyperandrogenism, which may often be manifested
as: hirsutism, acne, seborrhea, alopecia, menstrual
irregularity, obesity and ovarian cysts. PCOS shows
reproductive and metabolic complications that must
be diagnosed and treated early due to the risk of
infertility, endometrial cancer and plurimetabolic
syndrome. Besides these complications, PCOS is
associated with high morbidity due to aesthetic
aspects that negatively affect women’s self-esteem.
Knowledge about the physiopathologic mechanisms
of this syndrome is very important for an appropriate
therapeutic approach.
CLASSIFICATION AND EPIDEMIOLOGY
The key findings for the diagnosis of PCOS are:
hyperandrogenism, chronic anovulation and
polycystic ovaries on ultrasound. However, other
conditions may present with these manifestations,
making differential diagnosis necessary. 
Only a third of the patients have the classical
form of the syndrome described by Stein and
Leventhal, defined by the presence of amenorrhea,
hirsutism and bilateral enlargement of the ovaries.
Therefore, in 1990, the conference of the National
Institutes of Health (NIH) suggested new diagnostic
criteria represented by clinical and/or biochemical
evidence of hyperandrogenism associated with
oligoamenorrhea, with the exclusion of other causes
of hyperandrogenism. In 2003, a new consensus was
established by the European Society for Human
Reproduction and Embryology and the American
Society for Reproductive Medicine in Rotterdan - The
Netherlands, which defined the syndrome as the
presence of two or more manifestations that
included, besides those defined by the NIH, the
presence of polycystic ovaries on ultrasound.2 In
2006, the Androgen Excess Society gave emphasis to
hyperandrogenism, suggesting that this would be a
mandatory criterion for the diagnosis of the
syndrome (Chart 1).3
PCOS affects women of childbearing age, with
no predilection for race, but the signs and symptoms
may differ in various ethnic groups. Prevalence varies
from 4-10%, depending on the diagnostic criteria
used.4, 5 By the Rotterdam criteria, the prevalence is
five times higher than that defined by the criteria of
the NIH. 6
PATHOGENESIS
The etiology of PCOS is not yet fully
understood. It is believed that there is multigenic
complex disorder, including abnormalities in the
hypothalamic-pituitary axis, steroidogenesis and
insulin resistance. 7
Abnormal steroidogenesis
Most authors consider that abnormal
steroidogenesis, of ovarian or adrenal origin, is the
primary disorder of PCOS. High concentrations of
circulating testosterone and dehydroepiandrosterone
(DHEA) occur in 60-80% and 20-25% of women with
PCOS, respectively. 6, 8 There is also an increase in
estradiol production by ovarian granulosa cells
associated with excess androgen levels. (Chart 2). 9
Insulin resistance
Over the last decade, it has been observed that
most women with PCOS have some degree of insulin
resistance, even non-obese ones. Studies suggest the
existence of genetic predisposition, which ends up
manifesting as a result of lifestyle and obesity. 
Hyperinsulinemia resulting from insulin
resistance leads to an increase in the production of
androgens and also in their biologically active
National Institutes of Health (NIH) – 1990 1. Clinical and / or biochemical evidence of hyperandrogenism *
2. Oligoamenorrhea
European Society for Human Reproduction and 1. Clinical and / or biochemical evidence of hyperandrogenism *
Embryology and the American Society for 2. Oligoamenorrhea
Reproductive Medicine - 2003 3. Polycystic ovaries on ultrasound
Androgen Excess Society - 2006 1. Clinical and / or biochemical evidence of hyperandrogenism †
2. Oligoamenorrhea
3. Polycystic ovaries on ultrasound
CHART 1: Diagnostic criteria for PCOS
* Other causes of hyperandrogenism should be excluded
† Essential for diagnosis
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portion. The common suggested mechanism for this
is associated with changes in insulin receptors and in
the enzyme that regulates the production of adrenal
and ovarian androgens. 10 The systemic effects of
hyperinsulinemia are described in chart 3.11, 12
Abnormalities in pituitary function:
An imbalance in the release of the luteinizing
hormone (LH) and the follicle stimulating hormone
(FSH) from the pituitary has been implicated in the
pathogenesis of PCOS. In patients with PCOS, the LH
/ FSH ratio is altered and the secretion of LH is higher
than that of FSH, resulting in increased androgen
production by theca cells and in anovulatory cycles. 12,
13 However, recent studies have shown that changes in
LH levels are a secondary and not primary event. 13
Thus, higher levels of circulating androstenedione
are observed, with a consequent increase in the
peripheral conversion of this hormone into testosterone.
Excess androgen levels alter the regulation of female
hormones, resulting in increased estrogen levels,
menstrual irregularities and infertility. 6, 7, 12
CLINICAL MANIFESTATIONS
The clinical dermatologic manifestations of
hyperandrogenism include: hirsutism, acne,
seborrhea, alopecia, and in severe cases, signs of
virilization. There is considerable heterogeneity in
clinical findings, as there may be variation in the same
patient over time. For instance, hyperandrogenism
may not determine peripheral manifestations, as seen
mainly in Asian women. 
Hirsutism
Hirsutism is defined as excessive growth of
terminal hair in androgen-dependent areas in women.
It is one of the most commonly used clinical criteria
for the diagnosis of excess androgen levels, being
observed in 50-80% of the patients with
hyperandrogenism. 14-16
The Ferriman-Gallwey scale is used for the
diagnosis of hirsutism. The disorder is considered
present when the score is ≥ 8. However, this score is
examiner-dependent and does not consider the
impact of hirsutism on the well being of the patient. 15-
18 There is no correlation of the score with androgen
levels, since the response of the pilosebaceous unit to
androgens varies considerably (Figure 1). 17, 19, 20
The formation of hair follicles occurs during
fetal development and their concentration reflects
ethnic differences. 
9
The speed of hair growth varies
according to genetic differences in the activity of the
enzyme 5α-reductase, which converts testosterone
into dihydrotestosterone (DHT), which is the most
potent metabolite. There are two isoenzymes of 5α-
reductase: type 1, present in the sebaceous glands and
skin of the pubic region, and type 2, found in hair
follicles, scalp and genital area. Differences in the
activity of the two enzymes determine the variation of
clinical presentations in women with
hyperandrogenism. It is established that hirsute
women have increased activity of 5α-reductase in the
hair follicles. The activity of 5α-reductase is stimulated
by hyperandrogenism, insulin-like growth factor (IGF)
Accelerates lipogenesis ? Increases production of free
fatty acids;
Reduced levels of SHBG;
Increased LH and FSH levels
CHART 3: Effects of Hyperinsulinemia
SHBG: sex hormone binding globulin
LH: Luteinizing Hormone
FSH: Follicle Stimulating Hormone
Increase of testosterone and DHEA Interferes with the maturation of follicles and the emergence of the dominant follicle
Reduces hepatic SHBG production 
Increase of estradiol Increased risk of endometrial and breast cancer
CHART 2: Effects of abnormal steroidogenesis
DHEA: Dehydroepiandrosterone 
SHBG: sex hormone binding globulin
FIGURE 1: Ferriman-Gallwey Scale  6
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and by insulin itself. 21
Testosterone and DHT determine alterations in
the hair and in its cycle. They irreversibly transform
vellus hair into terminal hair, thicker and more
pigmented, in androgen-sensitive areas (face, neck,
chest and pubic region), after months or years of
exposure.16, 17 The duration of the anagen phase is also
related to levels of circulating androgens and varies in
the different regions of the body. Androgens prolong
the anagen phase in follicles of the body and shorten
it in some areas of the scalp. 16
To differentiate hirsutism from hypertrichosis
in women, it is necessary to determine the type of
excess hair and its distribution. Hypertrichosis is
excessive hair in the entire body; the growth of vellus
hair in androgen-independent areas, such as forearms
and calves, is also considered a manifestation of the
disease. Excess of vellus hair alone does not reflect
hyperandrogenism, as the former may be associated
with hereditary factors, medication, metabolic
disorders or physical irritation of the skin.17 In
hirsutism there is an increase of terminal hair in
androgen-dependent areas.
Acne
Acne is a pilosebaceous unit disorder with
lesions on the face, neck, back and pectoral region. 
The importance of androgens in the
pathogenesis of acne is well documented. However,
since in acne vulgaris androgen levels are usually
normal, it is believed that local conversion is
enhanced by increased receptor sensitivity to
androgens in acne patients as compared with the
normal population, perhaps representing the most
important triggering factor of the disease . 15.22
Androgens not only enlarge the sebaceous
glands and increase sebum production, but also cause
abnormal desquamation of follicular epithelial cells.
These factors determine the formation of comedones
and, in combination with the colonization of the
follicle by Propionibacterium acnes, result in
inflammation and progressive development of
papules, pustules, nodules, cysts and scars. 9
Several studies attempt to correlate the clinical
presentation of acne with markers of
hyperandrogenism. Although some authors have
shown a correlation between acne and high levels of
dehydroepiandrosterone sulfate (DHEA-S), DHT,
androstenedione, testosterone and IGF, others did
not corroborate this finding. 15, 20-22
Androgenetic Alopecia
Androgenetic alopecia in women is
characterized by loss of hair in the central region of
the scalp, with relevant psychosocial repercussions. 
In the presence of androgen, high levels of 5-
alpha reductase, higher concentration of androgen
receptors and lower levels of the enzyme cytochrome
p450, the anagen phase is shortened, and the terminal
follicles undergo miniaturization, turning into vellus
hair. 16, 21 Changes may occur diffusely, but they are
usually more evident in the frontal and parietal
regions.
The diagnosis should exclude other causes of
hair loss in women, such as telogen effluvium,
alopecia areata, anagen loss syndrome and
trichotillomania. 15
Most patients with androgenetic alopecia have
normal endocrine function. Thus, physical
examination and medical history are important in the
search for other signs of hyperandrogenism. 23
Additional tests may be needed, such as hair density,
hematological and biochemical evaluations, and
histological examination of the scalp to demonstrate
miniaturized hair.
Acanthosis nigricans
Acanthosis nigricans is characterized by brown
and velvety hyperpigmentation of the skin with
accentuation on skin folds. It is most commonly
observed in the neck and intertriginous areas, such as
armpits, groins and inframammary region. It is
reported in 5% of the patients with PCOS. 9
Excessive binding of serum insulin to IGF-1
receptors in peripheral tissues determines the
proliferation of keratinocytes and fibroblasts; hence,
acanthosis nigricans is a cutaneous manifestation of
hyperinsulinemia, and not just of obesity.
Histologically there is papillomatosis, hyperkeratosis
and acanthosis with minimal or no
hyperpigmentation of the basal layer. 
Despite being mostly associated with obesity,
PCOS and diabetes, acanthosis nigricans may be
associated with genetic diseases, drug reaction
(nicotinic acid) and malignancies. 15 
The presence of acanthosis nigricans suggests
the performance of the glucose tolerance test. 24 When
severe, extensive and progressive, it may be associated
with malignancy, especially if mucous membranes are
also involved. 15
Other Complications
The dysfunction of multiple hormone systems
that characterize PCOS determines increased risk for
many diseases. 8 It is therefore important to evaluate
and monitor patients to reduce morbidity and clinical
implications.
Glucose intolerance and diabetes are
considered the most important disorders in women
with PCOS. 6, 9, 25 There is no consensus, but it is
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believed that PCOS is related to increased risk for
cardiovascular disease. 8, 26 However, clinical
observations did not show greater morbidity and/or
mortality in women with PCOS, despite the
recognized association between insulin resistance and
lipid profile changes. 8, 9, 12 
Because PCOS is associated with irregular
menstrual cycles, women may experience difficulty
getting pregnant, endometrial hyperplasia and
endometrial carcinoma. 9, 12 These patients have a
higher prevalence of abortion, ovarian and breast
cancer, nonalcoholic steatohepatitis, obstructive sleep
apnea and symptoms of depression. 8, 9, 27
Evaluation
The clinical diagnosis of PCOS is based on
specific diagnostic criteria (Chart 4), but due to
variable symptomatology, close attention to signs and
symptoms is required. 6, 10
Clinical evaluation
The evaluation should include detailed
menstrual history, information about the onset and
duration of symptoms suggestive of
hyperandrogenism and family history of PCOS and
metabolic diseases 8-10,28. Abrupt changes in the
menstrual pattern or symptoms of hyperandrogenism
should alert us to other etiologies 28.
The most frequent clinical manifestations
include menstrual irregularity or amenorrhea, which
can be masked by the use of oral contraceptives (OC).
However, some women with PCOS have regular
ovulatory cycles. 
Examination of the genital region can be
accomplished using the Tanner Scale, which analyzes
the development of primary and secondary sexual
characteristics and identifies signs of virilization.
Clitoromegaly and voice changes are rare findings
suggestive of adrenal tumors 10.
Laboratory Evaluation
The main feature to confirm PCOS is the
detection of excessive androgen levels through
laboratory tests, although consensus allows only
clinical evidence of hyperandrogenism 17, 29.The
recommendation of the Endocrine Society in 2008 for
the evaluation of serum androgen levels in hirsute
patients is listed below (Chart 5).
Among androgens, testosterone is the primary
hormone in the evaluation of hirsutism and PCOS.
However, most available methods are not very
accurate, so their analysis should be cautious 17, 29.The
most sensitive and precise methods are
radioimmunoassays and tandem mass spectrometry. 
Free testosterone is the most sensitive for the
detection of hyperandrogenism 10, 29.This is because
sex hormone-binding globulin (SHBG), which is the
main determinant of the bioactive portion of plasma
testosterone (free or bioavailable testosterone), is
reduced in patients with hyperandrogenism. No tests
are available for the direct measurement of this
hormone. The best method is to calculate it by the
product of total testosterone and SHBG function (e.g.,
free testosterone = total testosterone x percentage of
free testosterone) 29, 30.These tests should be
performed early in the morning, between the 4th-10th
days of the menstrual cycle (women with regular
cycles) or in women with amenorrhea. Patients with
symptoms consistent of PCOS but without
testosterone level changes must repeat the exam. 
The dosage of other androgens in most cases is
of little use. However, it is necessary to exclude other
relatively common conditions that have specific
treatment. The tests usually required and their main
indications are listed in chart 6. 
If the screening for disorders that most
commonly mimic PCOS is negative, the association of
high levels of testosterone and anovulatory symptoms
meet the criteria for this syndrome. However, other
rare disorders associated with androgen excess
cannot be ruled out and an expert evaluation should
be conducted to determine the source of androgen
excess in these cases 17.
Two of the three criteria below and exclusion of other
etiologies (e.g., congenital hyperplasia, androgenic
tumors, Cushing syndrome)
1. Oligo and / or anovulation
2. Clinical and / or biochemical signs of hyperandrogenism
3. Polycystic ovaries 
CHART 4: Diagnostic Criteria for PCOS
• Moderate to severe hirsutism (score> 15)
• Hirsutism (any grade) of sudden and progressive onset 
• Hirsutism (any grade) associated with any of the fol
lowing findings:
Menstrual irregularity or infertility;
Central obesity;
Acne, seborrhea, alopecia 
Acanthosis nigricans;
Rapid progression;
Clitoromegaly;        
CHART 5: Evidence for assessment of serum androgen
levels
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The LH / FSH ratio is no longer recommended
for routine diagnosis of PCOS 2.This is because there
are differences between the data supplied by various
tests (radioimmunoassay with polyclonal antibodies,
monoclonal antibody radioimmunoassay,
immunometric assays), body mass index of the
patient and day of the cycle in which the test is done.
Moreover, the relationship of the LH/FSH ratio in the
pathogenesis of PCOS has not been confirmed.
However, FSH is important in the diagnosis of
primary ovarian failure, when FSH levels are high in
relation to LH and estrogen 31.
Among other laboratory tests, it is important to
remember the metabolic changes that may be related
to PCOS, since they are associated with high
morbidity. The glucose tolerance test should be
requested of obese women and those at risk for type
2 diabetes, such as family history 10. Periodic
assessment of lipid profile is recommended, as well as
liver function monitoring when there are risk factors
for hepatic steatosis (nonalcoholic fatty liver disease)
11, 32.
Radiological Assessment
Indication of pelvic ultrasonography is still
controversial. The classical presentation of PCOS is
characterized by ovaries with a polycystic aspect, with
more than eight subcortical cysts smaller than 10 mm
and/or increased ovarian volume (> 10ml) 2. The
examination should be performed early in the
follicular phase of the cycle (third to fifth day). In
oligo / amenorrheic patients, the exam may be
performed randomly or after 3-5 days of bleeding
induced by progestogens. However, 20% of the
patients did not reveal changes on ultrasound 6.
Moreover, many healthy women or those with other
disorders related to excess androgens may have
polycystic ovaries to the examination without
presenting the other findings of the syndrome 29.
TREATMENT
The treatment of PCOS seeks to reduce the
signs of hyperandrogenism, restore regular ovulatory
cycles and control features of the metabolic
syndrome. The choice of treatment will depend on
the severity of the symptoms and specific goals, always
considering the possible long-term consequences. 
Changes in lifestyle 
It is the most effective and inexpensive
approach, without adverse reactions. It consists in the
practice of regular physical activity and in the
adoption of a balanced diet. The loss of only 2-7% of
weight improves almost all the parameters of PCOS by
reducing androgen levels and improving ovarian
function 10. These effects are related to the reduction
in insulin levels and improvement of insulin
resistance 33.
Hormonal Treatment
The estrogen-progesterone combination
therapy remains the main option for the treatment of
hyperandrogenism for women who do not wish to
become pregnant. It can be effective for hirsutism,
Exam Indication
Pregnancy Test Amenorrhea
Prolactin Dosage Irregular menstrual cycles, to exclude prolactinoma 
DHEA Dosage Cystic acne, suspicion of a virilizing tumor 
17-hydroxyprogesterone dosage * High risk of adrenal hyperplasia, such as positive family history and 
ethnic groups at high risk (Ashkenazi Jewish, Hispanic and Slavic women) 
TSH Irregular menstrual cycles, oligoamenorrhea
Dexamethasone suppression test / Other findings, Cushing Syndrome
24h urinary cortisol
Dosage Somatomedin C / IGF-1 Other findings suggestive of acromegaly
CHART 6: Assessment of disorders that most commonly mimic PCOS
* It should be performed early in the morning, in the follicular phase of the menstrual cycle 
DHEA: Dehydroepiandrosterone
TSH: thyroid-stimulating hormone
IGF-1: Insulin Growth Factor-like type 1
Polycystic ovary syndrome: a dermatologic approach 117
An Bras Dermatol. 2011;86(1):111-9.
acne and androgenic alopecia, and to prevent
endometrial hyperplasia and its complications 14.
Oral contraceptives (OC) are composed of
ethinyl estradiol and a progestin. Estrogen suppresses
the LH, decreasing androgen production by the
ovaries and increasing the production of SHBG,
reducing free testosterone 17, 33.
Most progestins are derivatives of testosterone
and have androgenic activity (Chart 7). 
Drospirenone (DRSP) and cyproterone acetate
(CPA) are not structurally related to testosterone and
act as androgen receptor antagonists 17. CPA also acts
on androgen receptors, has little inhibitory effect on
5-·-reductase and reduces the secretion of androgen
through anti-gonadotropin action 17, 34. It may be used
as monotherapy in some cases.
Drospirenone is a spironolactone analogue
with equivalent effect to a dose of 25mg. It acts as anti-
mineralocorticoid, but has a weaker anti-androgen
action 17.
The main OC used for the treatment of
hirsutism contains CPA associated with estrogen. 33
Some studies confirm its efficacy, with a more rapid
reduction in hair growth when compared with other
anti-androgens. Similar efficacy has been observed
with OC constituted by drospirenone 17.
The use of OC should be maintained until
reproductive maturity, approximately 5 years after
menarche or until the ideal weight. The normalization
of menstrual cycles and the improvement of acne and
hirsutism occur, in general, three months after the
start of the treatment. Some studies have shown that
suppression of serum androgens remains for at least 2
years after discontinuation of OC, although most
patients experience worsening three months after the
end of treatment 10.
Worsening of insulin resistance and increased
levels of triglycerides and cholesterol associated with
OC use have been reported 33. Other side effects
include hypercoagulability, thrombogenic (mainly
CPA) and vascular reactivity, demanding caution in
patients with a history of vascular diseases such as
migraine 10.
Anti-androgenic drugs block the binding of
androgens to their tissue receptors or inhibit the 5α-
reductase enzyme. All anti-androgens should be
prescribed in combination with oral contraceptives
due to menstrual irregularities and risk of incomplete
virilization of male embryo during pregnancy 35. In the
treatment of hirsutism, they revert the transformation
induced by androgens of vellus hair into terminal
hair. Due to the long cycle of terminal hairs, the effect
is only observed 9-12 months after the initiation of
treatment 10.
Spironolactone, an aldosterone antagonist, has
dose-dependent action, blocking the binding of 5-
alpha dihidrotestosterone to androgen receptors of
the skin, increasing SHBG, reducing the activity of 5-
α-reductase and androgen production. It is effective
in treating hirsutism and it is believed that it could
also improve acne and alopecia. It is generally well
tolerated, although hypotension, polyuria, nausea,
headache, fatigue and menstrual irregularity have
been reported 10, 17, 33. The therapeutic regimen for
hirsutism is 25 to 100mg twice daily and for acne,
100mg once daily 15. The initial dose should be 25 mg
/ day and increased progressively over weeks 10.
Hyperkalemia has been reported only in women with
renal dysfunction or in those taking other potassium-
sparing medication. 
Flutamide, a potent nonsteroidal anti-
androgen, blocks the action of androgens by
competitive inhibition of receptors, while reducing
androgen synthesis or increasing its inactivation 35.
The recommended dose is 250 to 750mg/day, but
lower doses (62.5 to 250 mg daily) also appear to be
effective. It is very effective in the treatment of
hirsutism, acne and alopecia, but it has a high cost
and risk of liver toxicity that is dose dependent and,
although rare, potentially fatal 17. The most common
side effect is dry skin due to reduced production of
sebum 33, 34. Its use is not authorized in Brazil.
Finasteride, a type 2 inhibitor of 5α-reductase,
blocks the conversion of testosterone into DHT 15, 17.
Despite the fact that the pilosebaceous unit has
predominantly type 1 enzyme, studies show a
beneficial effect in the treatment of hirsutism, as well
as that of androgenic alopecia in women, with few
side effects 10. However, it does not seem to be
effective in treating acne. The dose used is 1 mg / day,
although safety at higher doses has been described 15.
Dutasteride acts on both isoenzymes 5α-
reductase and induces an even greater reduction in
serum levels of DTH, with evidence of benefit in the
treatment of female androgenic alopecia at a dose of
0.5 mg / day 23, 36.
Creams with anti-androgens have limited
effectiveness. No benefit has been found with the use
of 5% canrenone, the active metabolite of
spironolactone. Studies have shown conflicting
results with topical finasteride 17, 37.
High androgenic activity Low androgenic activity
Levonorgestrel Norgestimate,
Nogestrel Desogestrel
Gestodene
CHART 7: Progestins with androgenic activity
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Insulin sensitizers
These drugs reduce both hyperinsulinemia and
hyperandrogenemia, in addition to their benefits on
lipid profile, blood pressure and ovulation 33, 38, 39. The
reduction in androgen levels occurs by direct
influence on ovarian steroidogenesis through the
decrease of insulin levels and increase of SHBG 15.
Treatment of hirsutism with these drugs is still
controversial, although studies have shown reduced
growth and thickness of hair, and improvement of
acne and acanthosis nigricans 15, 38, 40, 41.
Metformin has been suggested as a first-choice
drug in the treatment of hirsutism in women with
PCOS, metabolic and reproductive disorders 10, 15, 34.
The initial dose is 500mg at dinner, which may be
increased every week until a maximum dose of
2000mg/day, divided into two doses 10. The effect
disappears 3 months after discontinuing the drug.
The most frequent side effects are dose dependent,
occurring nausea and diarrhea. Lactic acidosis is rare
and insignificant when young subjects with PCOS are
evaluated 10, 27.
These effects can also be obtained with
pioglitazone and rosiglitazone, and they may be
greater with the combination of oral contraceptive or
flutamide 40, 42. However, the safety of treatment with
these drugs still needs further evaluation. Patients
should be informed of the chance of spontaneous
ovulation.
Cosmetic treatment
Cosmetic procedures are important in the
treatment of hirsutism, which may be sufficient to
control mild to excessive hair growth or as an
adjuvant in severe cases. Shaving, depilation or
destruction of the dermal papilla by electrolysis or
laser may be performed. Hair removal using wax is
discouraged for patients with more severe cases of
hirsutism. This technique can be effective, but there is
a risk of skin irritation, folliculitis and ingrown hairs.
Laser epilation is the most effective method and,
despite the high cost, requires fewer sessions and the
results are better. 
Eflornithine hydrochloride is an irreversible
inhibitor of ornithine decarboxylase, which was
recently released for topical use in the treatment of
facial hirsutism. This enzyme is modulated by
androgens and regulates cell proliferation in the
matrix of the follicle. Studies have shown significant
reduction in the amount of hair, but the effect is
rapidly reversed after discontinuation of the drug.
Topical retinoids like calcipotriene and keratolytic
drugs, such as ammonium lactate, can be useful in the
treatment of acanthosis nigricans, as long as
hyperinsulinemia is controlled 15 , 43.
Besides systemic treatment, alopecia can be
controlled with topical minoxidil 2 or 5% and if
necessary, with hair transplant 23, 44.
CONCLUSION
Polycystic ovary syndrome is a common
endocrinopathy that affects women of reproductive
age, which may cause metabolic disorders and
psychosocial problems. Early diagnosis is essential for
the prevention of complications and we should be
attentive to the variety of clinical findings. Although its
etiology has not yet been fully elucidated, knowledge
and understanding of the abnormality in the
hypothalamus-pituitary axis, steroidogenesis and
insulin resistance are of utmost importance for early,
effective and safe treatment. 
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